-
公开(公告)号：EP1549767A2
公开(公告)日：2005-07-06
申请号：EP03770469.9
申请日：2003-09-25
发明人： DOBIE, Kenneth, W. , BHANOT, Sanjay , VENIANT-ELLISON, Murielle , LINDBERG, Richard, A. , SHUTTER, John, R.
CPC分类号： C12N15/113 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , Y02P20/582 , C12N2310/3525
摘要： Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particulary antisense oligonucleotides, targeted to nucleid acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
-
2.发明公开ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 FOR OCULAR THERAPIES 审中-公开针对血管生成素-1和血管生成素-2治疗眼科治疗的抗体
公开(公告)号：EP3207059A1
公开(公告)日：2017-08-23
申请号：EP15794675.7
申请日：2015-10-16
申请人： Amgen Inc.
发明人： LU, Shu-Chen , VENIANT-ELLISON, Murielle , XU, Jing , SALIMI-MOOSAVI, Hossein , OLINER, Jonathan D.
IPC分类号： C07K16/22 , A61K39/395 , A61K39/00
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/55 , C07K2317/76
摘要： The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.
摘要翻译： 本公开提供了使用抗血管生成抗体和药物制剂来治疗眼部疾病的方法。
-
公开(公告)号：EP2007804A2
公开(公告)日：2008-12-31
申请号：EP07761068.1
申请日：2007-04-20
申请人： Amgen, Inc
发明人： GEGG, Colin Victor, Jr., , MIRANDA, Leslie Phillip , WINTERS, Katherine Ann , VENIANT-ELLISON, Murielle
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.
-
4.发明公开GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES 审中-公开多肽ON）MS MS MS UN TOR TOR TOR 15（GDF-15）
公开(公告)号：EP2807266A1
公开(公告)日：2014-12-03
申请号：EP13741489.2
申请日：2013-01-28
申请人： Amgen Inc.
发明人： XIONG, Yumei , ZHANG, Yi , SHENG, Jackie Zeqi , HAMBURGER, Agnes Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN,Gunasekaran , WALKER, Kenneth, W. , LEMON, Bryan
摘要： GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
摘要翻译： 提供GDF15多肽，包含GDF15的构建体及其突变体。 在各种实施方案中，GDF15多肽，包含GDF15的构建体及其突变体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰岛素水平升高和糖尿病性肾病。
-
公开(公告)号：EP2015776A1
公开(公告)日：2009-01-21
申请号：EP07761070.7
申请日：2007-04-20
申请人： Amgen Inc.
发明人： SHEN, Wenyan , GRAHAM, Kevin , WINTERS, Katherine, Ann , VENIANT-ELLISON, Murielle , BOONE, Thomas, Charles
IPC分类号： A61K39/395 , C07K14/605 , C07K16/26
CPC分类号： C07K16/26 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： Compositions comprising antibodies that bind glucagon linked to GLP-I compounds are provided, as well as methods of using the compositions for treating, for example, metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a subject.
-
公开(公告)号：EP2807266B1
公开(公告)日：2020-01-15
申请号：EP13741489.2
申请日：2013-01-28
申请人： Amgen Inc.
发明人： XIONG, Yumei , ZHANG, Yi , SHENG, Jackie Zeqi , HAMBURGER, Agnes Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN,Gunasekaran , WALKER, Kenneth, W. , LEMON, Bryan
IPC分类号： C07K14/475 , A61K38/00 , A61K39/00 , C07K19/00
-
公开(公告)号：EP3355908A1
公开(公告)日：2018-08-08
申请号：EP16782352.5
申请日：2016-09-30
申请人： Amgen Inc.
发明人： XU, Jing , STANISLAUS, Shanaka , CHEN, Mei-Hsiu M. , HALE, Clarence H. , VENIANT-ELLISON, Murielle
CPC分类号： A61K38/1825 , A61P1/00 , A61P1/16
摘要： The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.
-
公开(公告)号：EP3027642B1
公开(公告)日：2020-08-19
申请号：EP14752711.3
申请日：2014-07-31
申请人： Amgen Inc.
发明人： XIONG, Yumei , ZHANG, Yi , SHENG, Jackie, Z. , HAMBURGER, Agnes, Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , MOCK, Marissa , WALKER, Kenneth
IPC分类号： C07K14/475 , A61P13/12 , A61P3/00
-
公开(公告)号：EP3683228A3
公开(公告)日：2020-07-29
申请号：EP20151691.1
申请日：2013-01-28
申请人： Amgen Inc.
发明人： XIONG, YuMei , ZHANG, Yi , SHENG, Jackie Zeqi , HAMBURGER, Agnes Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , WALKER, Kenneth W. , LEMON, Bryan
IPC分类号： C07K14/475 , A61K39/00
摘要： GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：EP3683228A2
公开(公告)日：2020-07-22
申请号：EP20151691.1
申请日：2013-01-28
申请人： Amgen Inc.
发明人： XIONG, YuMei , ZHANG, Yi , SHENG, Jackie Zeqi , HAMBURGER, Agnes Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , WALKER, Kenneth W. , LEMON, Bryan
IPC分类号： C07K14/475 , A61K39/00
摘要： GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.017 秒)
